CS-1020 / CS Group - LARVOL DELTA

[VIRTUAL] Discovery of novel STING agonists with robust anti-tumor activity (AACR-II 2020) - "Compounds-treated mice free from tumor for 30 days were re-challenged with MC38 tumor cells in MC38 murine model. Several lead compounds CS-1018, CS-1020 and CS-1010 activate mouse and human STING variants in vitro with much better potency than natural ligand cGAMP and reference compound X. CS-1018 demonstrated dose dependent robust antitumor activity in B16F10 and MC38 mouse models. We have identified several STING agonists, which demonstrated better cellular potency to mouse and human STING alleles compared to natural ligand cGAMP and reference compound. All compounds showed dose dependent antitumor activity in MC38 or B16F10 syngeneic models, in addition, tumor-free mice after treatment of compounds developed tumor specific immunologic memory response in MC38 murine model. Combination studies of identified STING agonists with other IO agents are currently ongoing."

Oncology • STING